26 min listen
HOT TOPICS - ANNEXA-I Trial
ratings:
Length:
61 minutes
Released:
Jun 19, 2024
Format:
Podcast episode
Description
Patients with acute intracerebral hemorrhage who are receiving factor Xa inhibitors have a risk of hematoma expansion. The effect of andexanet alfa, an agent that reverses the effects of factor Xa inhibitors, on hematoma volume expansion had not been well studied, until the ANNEXA-I Trial. To discuss this week's Hot Topic, Nicholas Morris, MD is joined by one of the trial's collaborators, Ashkan Shoamanesh, MD as well as clincial pharmacist Andrew Webb, PharmD, BCCCP. Listeners can also join the NCS Journal Club which will be discussing the ANNEXA-I Trial on "X" / Twitter on Tuesday, July 16th starting at 9am CT.
Released:
Jun 19, 2024
Format:
Podcast episode
Titles in the series (100)
May 14, 2021: Procalcitonin Is Not an Adequate Tool for Antimicrobial De-Escalation in Sepsis: On today's episode, Holly Ledyard, MD, MS is joined by Ryan Maves, MD, FCCP, FCCM, FIDSA to discuss his recent article, "." NCS offers free CE credits for the NCS Podcast Series episodes. Listen to any of the posted episodes, complete a... by Neurocritical Care Society Podcast